Philis-Tsimikas A, et al. - In the DUAL IX trial, researchers examined insulin degludec/liraglutide (IDegLira) vs insulin glargine 100 units/mL (IGlar U100) as an add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy in terms of effectiveness and safety. They randomized insulin-naïve patients ≥18 years with HbA1c 7.0–11.0%, BMI 20–40 kg/m², and inadequately controlled type 2 diabetes (T2D) on SGLT2 inhibitor ± oral antidiabetic drugs 1:1 to once-daily IDegLira or IGlar U100, both as add-on to existing therapy in this 26-week, phase 3b, open-label, parallel-group, treat-to-target trial at 74 sites in 11 countries. Among patients with uncontrolled T2D on SGLT2 inhibitor, IDegLira had favorable safety and effectiveness profile, and led to lower weight gain and hypoglycemia risk vs IGlar U100. This study favors IDegLira initiation in this population.